Catalina Le Roy1, Martina Meier2, Scarlett Witting3, Francisco Pérez-Bravo4, Carlos Solano5, Carlos Castillo-Durán6. 1. Pediatra, Nutriólogo, Departamento de Pediatría, Facultad de Medicina Campus Centro, Universidad de Chile, Santiago de Chile, Chile; Pediatra, Nutriólogo, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile. Electronic address: catalinaleroy@yahoo.es. 2. Alumna 6.° año de Medicina, Facultad de Medicina, Universidad de Chile, Santiago de Chile, Chile. 3. Neuróloga Infantil, Servicio Neuropsiquiatría Infantil, Hospital Clínico San Borja-Arriarán, Santiago de Chile, Chile; Neuróloga Infantil, Departamento de Pediatría, Facultad de Medicina Campus Centro, Universidad de Chile, Santiago de Chile, Chile. 4. Bioquímico, Departamento de Nutrición, Facultad de Medicina, Universidad de Chile, Santiago de Chile, Chile. 5. Bioquímico, Laboratorio Inmunología, Hospital Clínico San Borja-Arriarán, Santiago de Chile, Chile. 6. Pediatra, Nutriólogo, Departamento de Pediatría, Facultad de Medicina Campus Centro, Universidad de Chile, Santiago de Chile, Chile.
Abstract
INTRODUCTION:Children with cerebral palsy (CP) have an increased risk of vitamin D (VD) deficiency. Although there are many studies on VD and CP, there is limited information about VD supplementation in these patients. OBJECTIVE: To evaluate the effect of supplementation with a single dose of VD on the plasma concentrations of 25-hydroxy-vitamin-D (25OHD) in children with CP. PATIENTS AND METHOD: Prospective-randomised-controlled-trial, including 30 Chilean children (19 males) with CP, median age 9.9 years (6.2-13.5). Clinical and biochemical variables including 25OHD, were recorded (time 0 and 8 weeks). Patients were allocated to the supplemented (S) group receiving 100,000 IU oral D3 at baseline, and compared with the placebo (P) group. RESULTS: Among clinical features are highlighted: gastrostomy (60%), underweight (30%), bed-ridden (93.3%), antiepileptic drugs (70%), and 43.3% used VD metabolism inducing antiepileptics. Baseline biochemical measurements were normal. The 25OHD was insufficient in 4/30 and deficient in 6/30. 25OHD levels were not associated with the variables studied. Eight patients completed the study in the S group, and 10 in P group. The placebo and supplementation groups had no significant difference in baseline variables. Serum calcium, phosphate, and alkaline phosphatase levels at 8 weeks were normal in both groups, with no statistically significant differences. 25OHD in the P group was normal in 6/10, and insufficient+deficient in 4/10, and the S group was normal in all (8/8) (exact Fisher test P=.07). CONCLUSIONS: A single dose of 100,000 IU VD could normalise the concentrations of 25OHD after 8 weeks of supplementation in Children with CP, but more studies are required to confirm these results.
RCT Entities:
INTRODUCTION:Children with cerebral palsy (CP) have an increased risk of vitamin D (VD) deficiency. Although there are many studies on VD and CP, there is limited information about VD supplementation in these patients. OBJECTIVE: To evaluate the effect of supplementation with a single dose of VD on the plasma concentrations of 25-hydroxy-vitamin-D (25OHD) in children with CP. PATIENTS AND METHOD: Prospective-randomised-controlled-trial, including 30 Chilean children (19 males) with CP, median age 9.9 years (6.2-13.5). Clinical and biochemical variables including 25OHD, were recorded (time 0 and 8 weeks). Patients were allocated to the supplemented (S) group receiving 100,000 IU oral D3 at baseline, and compared with the placebo (P) group. RESULTS: Among clinical features are highlighted: gastrostomy (60%), underweight (30%), bed-ridden (93.3%), antiepileptic drugs (70%), and 43.3% used VD metabolism inducing antiepileptics. Baseline biochemical measurements were normal. The 25OHD was insufficient in 4/30 and deficient in 6/30. 25OHD levels were not associated with the variables studied. Eight patients completed the study in the S group, and 10 in P group. The placebo and supplementation groups had no significant difference in baseline variables. Serum calcium, phosphate, and alkaline phosphatase levels at 8 weeks were normal in both groups, with no statistically significant differences. 25OHD in the P group was normal in 6/10, and insufficient+deficient in 4/10, and the S group was normal in all (8/8) (exact Fisher test P=.07). CONCLUSIONS: A single dose of 100,000 IU VD could normalise the concentrations of 25OHD after 8 weeks of supplementation in Children with CP, but more studies are required to confirm these results.